规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
100g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
在肌腱细胞中,环丙沙星 (Bay-09867) 盐酸盐一水合物(5–50 μg/mL;0–24 小时)可抑制细胞生长并诱导细胞周期停滞在 G2/M 期[1]。盐酸环丙沙星 (Bay-09867) 一水合物的 MIC90 分别为 0.03 μg/mL 和 0.12 μg/mL,对鼠疫耶尔森菌和炭疽芽孢杆菌表现出强烈的作用[2]。
|
---|---|
体内研究 (In Vivo) |
受到环丙沙星 (Bay-09867) 盐酸盐一水合物的保护(30 mg/kg;腹腔注射;持续 24 小时;BALB/c 小鼠)。小鼠肺鼠疫模型中的鼠疫菌[3]。通过降低主动脉壁中的 LOX 水平并提高 MMP 水平和活性,环丙沙星 (Bay-09867) 盐酸盐一水合物(100 mg/kg;ig;每天,持续 4 周;C57BL/6J 小鼠)加速主动脉根部扩张并提高发病率主动脉夹层和破裂的发生[4]。 Ciprofloxacin (Bay-09867) 盐酸盐一水合物(100 mg/kg;ig;每天,持续 4 周;C57BL/6J 小鼠)会导致线粒体功能障碍、胞质 DNA 传感器信号激活以及 DNA 损伤并释放到胞质中。乳酸环丙沙星可增加主动脉壁的细胞凋亡和坏死性凋亡[4]。
|
细胞实验 |
细胞活力测定[1]
细胞类型: 肌腱细胞 测试浓度: 5、10、20 和 50 µg /mL 孵化持续时间:24 小时 实验结果:减少了肌腱细胞的细胞结构。 细胞周期分析[1] 细胞类型: 肌腱细胞 测试浓度: 50 μg/mL 孵育时间:24小时 实验结果:细胞周期被阻滞在G2/M期,并抑制肌腱细胞的细胞分裂。 蛋白质印迹分析[1] 细胞类型: 肌腱细胞 测试浓度: 50 μg/mL 孵育时间:0、6、12、17和24小时 实验结果:下调CDK-1和cyclin B蛋白及mRNA的表达。上调PLK-1蛋白的表达。 |
动物实验 |
Animal/Disease Models: balb/c (Bagg ALBino) mouse[3]
Doses: 30 mg/kg Route of Administration: intraperitoneal (ip)injection; for 24 hrs (hours) Experimental Results: decreased the lung bacterial load in murine model of pneumonic plague. Animal/Disease Models: C57BL/6J mice[4] Doses: 100 mg/kg Route of Administration: po (oral gavage); daily, for 4 weeks Experimental Results: Had aortic destruction that was accompanied by diminished LOX expression and increased MMP expression and activity. Animal/Disease Models: C57BL/ 6J mice[4] Doses: 100 mg/kg Route of Administration: po (oral gavage); daily, for 4 weeks Experimental Results: Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall. |
参考文献 |
[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.
[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16. [3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91. [4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. |
分子式 |
C17H21CLFN3O4MOLECULARWEIGHT
|
---|---|
分子量 |
385.8177
|
CAS号 |
86393-32-0
|
相关CAS号 |
Ciprofloxacin;85721-33-1;Ciprofloxacin monohydrochloride;93107-08-5;Ciprofloxacin-d8 hydrochloride monohydrate
|
SMILES |
Cl[H].FC1C([H])=C2C(C(C(=O)O[H])=C([H])N(C2=C([H])C=1N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])C1([H])C([H])([H])C1([H])[H])=O.O([H])[H]
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO : ~5 mg/mL (~12.96 mM)
|
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5919 mL | 12.9594 mL | 25.9188 mL | |
5 mM | 0.5184 mL | 2.5919 mL | 5.1838 mL | |
10 mM | 0.2592 mL | 1.2959 mL | 2.5919 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。